ASH China Voice | Professor Wang Liang: Dual-Target Breakthrough, Promising Combinations — Interpretation of a Phase II Study of CD19/CD22 CAR-T Therapy in R/R LBCL 

ASH China Voice | Professor Wang Liang: Dual-Target Breakthrough, Promising Combinations — Interpretation of a Phase II Study of CD19/CD22 CAR-T Therapy in R/R LBCL 

2025.12.24
Despite the remarkable progress achieved with single-target CAR-T therapy in the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL), a proportion of patients still experience suboptimal responses or relapse after treatment. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Wang Liang from Beijing Tongren Hospital, Capital Medical University, was selected for an oral presentation, reporting impressive results from a phase II clinical trial of dual-target CD19/CD22 CAR-T cell therapy in R/R LBCL. The findings attracted wide attention. Hematology Frontier invited Professor Wang Liang for an in-depth discussion of the innovative aspects of this study, offering valuable insights for future optimization of R/R LBCL treatment strategies and research directions.
ASH China Voice | Professor Zhao Yanmin: Precision Exploration in Hematopoietic Stem Cell Transplantation — From HLA Evolutionary Divergence Assessment to Post-Transplant Maintenance Strategies 

ASH China Voice | Professor Zhao Yanmin: Precision Exploration in Hematopoietic Stem Cell Transplantation — From HLA Evolutionary Divergence Assessment to Post-Transplant Maintenance Strategies 

2025.12.24
At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang He from the First Affiliated Hospital of Zhejiang University School of Medicine presented multiple innovative studies in the field of hematopoietic stem cell transplantation. These studies covered in-depth analyses of HLA evolutionary divergence (HED), post-transplant maintenance with epigenetic regulatory agents, and other cutting-edge topics, highlighting an integrated translational medicine strategy aimed at addressing key clinical challenges, comprehensively improving transplant outcomes, and enhancing long-term patient survival and quality of life. During the meeting, Hematology Frontier invited Professor Zhao Yanmin from the First Affiliated Hospital of Zhejiang University School of Medicine to systematically interpret the team’s core research achievements, elucidate their clinical value, and discuss future development directions, providing valuable insights for both academic research and clinical practice.
Voices from ASH China丨Professor Sun Ruijuan: Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Infant Acute Leukemia

Voices from ASH China丨Professor Sun Ruijuan: Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Infant Acute Leukemia

2025.12.24
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando, USA. As the world’s largest and most influential international academic conference in the field of hematology, the ASH Annual Meeting attracts tens of thousands of experts and scholars each year to share the latest advances and breakthrough research. At this year’s meeting, a study led by Professor Sun Ruijuan from Lu Daopei Hospital was selected for poster presentation, focusing on the clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia, providing important insights for the treatment of this challenging patient population. Hematology Frontier invited Professor Sun to share the details of this study for academic exchange.